Galapagos NV increased its staff by 45% in the year to 31 March in anticipation of the launch of its first pharmaceutical, filgotinib, on global markets. The Belgian company reported an operating loss of €44.6 million in the first quarter, but this was dwarfed by cash and cash equivalents of €5.7 billion, the result of successful equity offerings and a lucrative partnership with Gilead Sciences Inc for filgotinib, which is in registration for rheumatoid arthritis.
